↓ Skip to main content

The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts

Overview of attention for article published in BMC Cancer, June 2015
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts
Published in
BMC Cancer, June 2015
DOI 10.1186/s12885-015-1445-0
Pubmed ID
Authors

Nipin SP, Pramod Darvin, Young Beom Yoo, Youn Hee Joung, Dong Young Kang, Don Nam Kim, Tae Sook Hwang, Sang Yoon Kim, Wan Seop Kim, Hak Kyo Lee, Byung Wook Cho, Heui Soo Kim, Kyung Do Park, Jong Hwan Park, Soung Hoon Chang, Young Mok Yang

Abstract

Combination therapy, which reduces the dosage intensity of the individual drugs while increasing their efficacy, is not a novel approach for the treatment of cancer. Methylsulfonylmethane (MSM) is an organic sulfur compound shown to act against tumor cells. Tamoxifen is a commercially available therapeutic agent for breast malignancies. In the current study, we analyzed the combinatorial effect of MSM and tamoxifen on the suppression of ER-positive breast cancer xenograft growth and metastasis. Additionally, we also validated the molecular targets by which the drug combination regulated tumor growth and metastasis. We observed that the combination of MSM and tamoxifen regulated cell viability and migration in vitro. The intragastric administration of MSM and subcutaneous implantation of tamoxifen tablets led to tumor growth suppression and inhibition of the Janus kinase 2 (Jak2)/signal transducer and activator of transcription 5b (STAT5b) pathway. Our study also assessed the regulation of signaling molecules implicated in the growth, progression, differentiation, and migration of cancer cells, such as Jak2, STAT5b, insulin-like growth factor-1Rβ, and their phosphorylation status. Study results indicated that this combination therapy inhibited tumor growth and metastasis. Therefore, this drug combination may have a synergistic and powerful anticancer effect against breast cancer.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 28%
Researcher 6 17%
Professor > Associate Professor 4 11%
Student > Doctoral Student 3 8%
Student > Ph. D. Student 3 8%
Other 5 14%
Unknown 5 14%
Readers by discipline Count As %
Medicine and Dentistry 6 17%
Biochemistry, Genetics and Molecular Biology 5 14%
Agricultural and Biological Sciences 4 11%
Chemistry 3 8%
Nursing and Health Professions 2 6%
Other 8 22%
Unknown 8 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 June 2015.
All research outputs
#17,763,547
of 22,813,792 outputs
Outputs from BMC Cancer
#4,959
of 8,299 outputs
Outputs of similar age
#177,648
of 264,785 outputs
Outputs of similar age from BMC Cancer
#128
of 196 outputs
Altmetric has tracked 22,813,792 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,299 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,785 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 196 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.